Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast

Chest

Volumn 121, Issue 3, 2002, Pages 732-738

  Minoguchi, Kenji ^a   Kohno, Yasurou ^a   Minoguchi, Hideko ^b   Kihara, Norio ^b   Sano, Yasuyuki ^b   Yasuhara, Hajime ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cysteinyl leukotriene 1 receptor antagonist; Eosinophil; Montelukast; Sputum

Indexed keywords

HISTAMINE; MONTELUKAST; PLACEBO; SODIUM CHLORIDE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATATION; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EOSINOPHIL; FEMALE; HUMAN; INFLAMMATION; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; SPUTUM ANALYSIS;

EID: 0036204826     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.3.732     Document Type: Article

References (35)

1. Pathophysiology of asthma
2. Treatment of asthma with drugs modifying the leukotriene pathway
3. The role and contribution of leukotrienes in asthma
4. Leukotrienes are potent constrictors of human bronchi
5. Leukotrienes and airway responses
6. 4 from the urine of patients with airway obstruction
7. Challenge studies of a leukotriene receptor antagonist
8. Leukotriene bronchoconstriction induced by allergen and exercise
9. Aspirin-induced asthma: Advances in pathogenesis and management
10. Pranlukast (Ultair) inhibits cold air-induced bronchoconstriction in patients with asthma
11. 4 receptor antagonist
12. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxygenase inhibitor
13. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078
14. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin
15. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid
16. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
17. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: An integrated analysis of zafirlukast trials
18. Characterization of the human cysteinyl leukotriene CysLT1 receptor
19. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids
20. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial
21. 4-receptor antagonism in the airways of patients with asthma
22. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma
23. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial
24. Committee for definition, treatment, management of adult asthma
25. Use of induced sputum cell counts to investigate airway inflammation in asthma
26. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma
27. Effect of theophylline withdrawal on airway inflammation in asthma
28. Induced sputum and eosinophilic inflammation
29. Sputum in severe exacerbations of asthma: Kinetics of inflammatory indices after prednisone treatment
30. 4 and granulocytic infiltration into asthmatic airways
31. 4 effects on human eosinophil and neutrophil motility in vitro
32. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals
33. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist
34. Asthma, inflammation, eosinophils, and bronchial hyperresponsiveness
35. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction